Skip to Main Content

Melanoma

Trial EIK1001-006
Cancer Type Melanoma
Hospital(s) Belfast City Hospital
Information

A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma (TeLuRide-006)

Trial Open Yes
Trial PerceIVe
Cancer Type Melanoma
Hospital(s) Belfast City Hospital
Information

Power of liquid biopsy tracking in immunotherapy treated stage IV melanoma

Trial Open Yes